

Therapie chronischer Schmerzen: Update

Teil 1: Einführung, Klassifikation und Nicht-Opioid-Analgetika

Traitement des douleurs chroniques: update

1^{ère} partie: introduction, classification des douleurs et traitement par analgésiques non-opioides

Literatur / Références

- 1 Merskey H, Bogduck N. Classification of chronic pain. IASP Press 1994.
- 2 Woolf C, Salter MW. Neuronal plasticity: Increasing the gain in pain. *Science*. 2000;288:1765–9
- 3 Manthyh PW, DeMaster E, Malhotra A, Ghilardi JR, Rogers SD, Rogers SD, et al. Receptor endocytosis and dendrite reshaping in spinal neurons after somatosensory stimulation. *Science*. 1995;16:268:1629–32.
- 4 Petrovic P, Ingvar M. Imaging cognitive modulation of pain processing. *Pain*. 2002;95:1–5.
- 5 Juottonen K, Gockel M, Silén T, Hurri H, Hari R, Forss N. Altered central sensorimotor processing in patients with complex regional pain syndrome. *Pain*. 2002;98:315–23.
- 6 Curatolo M, Arendt-Nielsen L, Petersen-Felix S. Central hypersensitivity in chronic pain: mechanism and clinical implications. *Phys Med Rehabil Clin N Am*. 2006;17:287–302.
- 7 Dworkin Rh, Turk DC, McDermott MP, Peirce-Sandner S, Burke LB, Cowan P, et al. Interpreting the clinical importance of group differences in chronic pain clinical trials: IMPACT recommendations. *Pain*. 2009;146:238–44.
- 8 Rados I, Sakic Zdravcevic K, Hrgovic Z. pain DETECT Questionnaire and lumbar epidural steroid injection for chronic radiculopathy. *Eur Neurol*. 2012;69:27–32.
- 9 Freyhagen R, Tölle T, Gockel U. painDETECT – ein Palmtop-basiertes Verfahren für Versorgungsforschung, Qualitätsmanagement und Screening bei chronischen Schmerzen. *Akt Neurol* 2005;32:273.
- 10 Hansson P, Backonja M, Bouhassira D. Usefulness and limitations of quantitative sensory testing: Clinical and research application in neuropathic states. *Pain*. 2007;129:256–59.
- 11 Aasvang EK, Gmaehle E, Hansen JB, Gmaehle B, Forman JL, Schwarz J et al. Predictive risk factors for persistent postherniotomy pain. *Anesthesiology*. 2010;112:957–69.
- 12 Eisenach JC. Preventing chronic pain after surgery: who, how, and when? *Reg Anesth Pain Med*. 2006;31:1–3.
- 13 Demyttenaere K, Bruffaerts R, Lee S, Posada-Villa J, Kovess V, Angermeyer MC et al. Mental disorders among persons with chronic back or neck pain: results from the World Mental Health Surveys. *Pain*. 2007;129:332–42.
- 14 Davies KA, Macfarlane GJ, McBeth J, Morriss R, Dickens C. Insecure attachment style is associated with chronic wide spread pain. *Pain*. 2009;143:200–5.
- 15 Tracey I. Can neuroimaging studies identify pain endophenotypes in humans? *Nat Rev Neurol*. 2011;7:173–81.
- 16 Garcia de Paredes ML, del Moral Ganzales F, Martinez de Prado P, Marti Ciriquian JL, Enrech Frances S, Cobo Dols M, et al. First evidence of oncologic neuropathic pain prevalence after screening 8615 cancer patients. *Ann Oncol*. 2011;22:924–30.
- 17 Ref. suchen zum Bsp. In Schw. Med. Forum
- 18 Lee YS, Kim H, Brahim JS, Rowan J, Lee G, Dionne RA. Acetaminophen selectively suppresses peripheral prostaglandin E2 release and increases COX-2 gene expression in a clinical model of acute inflammation. *Pain*. 2007;129:279–86.
- 19 Mallet C, Daulhac L, Bonnefont J, Ledent C, Etienne M, Chapuy E, et al. Endocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia. *Pain*. 2008;139:190–200.
- 20 Bandschapp O, Filitz J, Urwyler A, Koppert W, Ruppen W. Tropicisetron blocks analgesic action of acetaminophen: a human pain model study. *Pain*. 2011;152:1304–10.
- 21 Koppert W, Wehrfritz A, Körber N, Sittl R, Albrecht S, Schüttler J, et al. The cyclooxygenase isoenzyme inhibitors parecoxib and paracetamol reduce central hyperalgesia in humans. *Pain*. 2004;108:148–53.

- 22 Maund E, McDaid C, Rice S, Wright K, Jenkins B, Woolacott N. Paracetamol and selective non-steroidal anti-inflammatory drugs for the reduction in morphine-related side-effects after major surgery: a systematic review. *Br J Anaesth*. 2011;106:292–7.
- 23 Faber K, Rauber-Lüthy, Kupferschmidt H, Ceschi A. Akute Paracetamol-Intoxikation. *Schweiz Med Forum*. 10(38):647–51.
- 24 Eyers S, Weatherall M, Jeffries S, Basley R. Paracetamol in pregnancy and the risk of wheezing in offspring: a systematic review and meta-analysis. *Clin Exp Allergy*. 2011;41:482–9.
- 25 Theiler R, Wyrsch B. Rationale Schmerztherapie – oder doch nicht? *Schweiz Med Forum*. 2012;12:645–51.
- 26 Ibanez L, Vidal X, Ballarin E, Laporte JR. Population-based drug-induced agranulocytosis. *Archiv Int Med*. 2005;165:869–74.
- 27 Theiler R, Wyrsch B. Rationale Schmerztherapie – oder doch nicht? *Schweiz Med Forum*. 2012;12:645–51.
- 28 Berg J, Fellier H, Christoph T, Grarup J, Stimmeder D. The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. *Inflamm Res*. 1999;48:369–79.
- 29 Hernandez-Dias S, Rodriguez LA. Association between non-steroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. *Arch Int Med*. 2000;160:2093–9.
- 30 Lanas A, Perez-Aisa MA, Feu F, Ponce J, Saperas E, Santolaria S, et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drugs. *Am J Gastroenterol*. 2005;100:1685–93.
- 31 Shankaran H, Alexandridis P, Neelamegham S. Aspects of hydrodynamic shear regulating shear-induced platelet activation and self-association of von Willibrand factor in suspension. *Blood*. 2003;101:2637–45.
- 32 Fitzgerald GA. COX-2 in play at the AHA and the FDA. *Trends Pharmacol Sci*. 2007;28:303–7.
- 33 Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal anti-inflammatory drugs: an update for clinicians. A scientific statement from the American Heart Association. *Circulation*. 2007;115:1634–42.
- 34 Tannenbaum H, Bombardier C, Davis P, Russel AS. The Third Canadian Consensus Conference Group. An evidence-based approach to prescribing nonsteroidal, anti-inflammatory drugs. *J Rheuma*. 2006;33:140–57.
- 35 Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. *BMJ*. 2011;342:c7086.
- 36 Vuolteenaho K, Moilanen T, Moilanen E. Non-steroidal anti-inflammatory drugs, cyclooxygenase-2 and the bone healing process. *Basic Clin Pharmacol Toxicol*. 2008;102:10–4.
- 37 Li Q, Zhang Z, Cai Z. High-dose ketorolac affects adult spinal fusion: a meta-analysis of the effect of perioperative nonsteroidal anti-inflammatory drugs on spinal fusion. *Spine*. 2011;36: E461–8.
- 38 Umbreit C, Virchow JC, Thorn C, Hörmann K, Klimek L Pfaar O. Aspirin Intoleranz-Syndrom: eine häufige und interdisziplinäre Erkrankung. *Internist*. 2010;51:1196–8.
- 39 Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. *BMJ*. 2011;342:c7086.
- 40 Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. Cyclooxygenaseinhibitors and the antiplatelet effects of aspirin. *N Engl J Med*. 2001;345:1809–17.
- 41 Capone ML, Sciulli MG, Tacconelli S, Grana M, Ricciotti E, Renda G, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. *J Am Coll Cardiol*. 2005;45:1295–1301.
- 42 White P, Raeder J, Kehlet H. Ketorolac: Its role as part of a multimodal analgesic regimen. *Anesth Analg*. 2012;114:250–54.
- 43 Feldmann HI, Kinman JL, Berlin JA, Hennessy S, Kimmel SE, Farrar J, et al. Parenteral Ketorolac: the risk for acute renal failure. *Ann Intern Med*. 1997;126:193–9.
- 44 Silverstein FE, Faich G, Goldstein H, Simon LS, Pincus T, Whelton A et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. *JAMA*. 2000;13:1247–55.
- 45 Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. MEDAL Steering committee. Assessment of upper GI safety of etoricoxib in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomized comparison. *Lancet*. 2007;369:465–73.
- 46 Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B et al. VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. *N Engl J Med*. 2000;343:1520–8.
- 47 Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Prevention on Vioxx (APPOVe). Cardiovascular events associated with rofecoxib in a colorectal adenoma prevention trial. *N Engl J Med*. 2005;352:1092–102.
- 48 ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized controlled Alzheimer's disease anti-inflammatory prevention trial. *PLoS Clin Trials*. 2006;1:e33.
- 49 Theiler R, Wyrsch B. Rationale Schmerztherapie – oder doch nicht? *Schweiz Med Forum*. 2012;12:645–51.
- 50 Argoff, Ch. Submicron particle diclofenac shows fast pain control. Poster abstract 25, Proceedings American Academy of Pain Management 23 rd Clinical Meeting Phoenix, Ariz. 2012.